In studies focusing on the application of aPD-1/aPD-L1 monotherapy in patient, one study involving 126 NSCLC patients treated with nivolumab demonstrated that PR/SD patients had significantly higher baseline levels of CD62Llow CD4+ T cells (CD62Llow indicates activation by antigen stimulation) and significantly lower levels of Treg (CD25+FOXP3+CD4+ T) cells, while patients with PFS > 500 days also exhibited a higher baseline percentage of CD62Llow CD4+ T cells [109]. The gene discussed is CD4; the disease is non-small cell lung carcinoma.